ECS 2 RIO Europe Lipids

Information about ECS 2 RIO Europe Lipids

Published on November 30, 2007

Author: Cubemiddle

Source: authorstream.com

Content

Clinical Evidence:  Clinical Evidence CB1 receptor blockade with rimonabant improved multiple cardiovascular and metabolic variables HDL-cholesterol, triglycerides, glucose metabolism, CRP and adiponectin Body weight and waist circumference Effects are probably mediated by peripheral and central actions 1 RIO: Rimonabant In Overweight/Obesity :  RIO: Rimonabant In Overweight/Obesity (>6600 patients enrolled) Pi-Sunyer FX.Obes Res. 2004;12(suppl):08-OR, A27. 1 2 RIO-Europe and RIO-Lipids: Study Design:  RIO-Europe and RIO-Lipids: Study Design Rimonabant 20 mg Van Gaal et al. The Lancet 2005; 365: 1389-97. Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. 3 RIO-Europe: Baseline Characteristics:  RIO-Europe: Baseline Characteristics Placebo Rimonabant (n=305) 5 mg (n=603) 20 mg (n=599) Race (white)* 290 (95.1%) 565 (93.7%) 555 (92.7%) Sex (female) 244 (80.0%) 476 (78.9%) 478 (79.8%) Age (years) 45.0 ± 11.6 45.4 ± 11.2 44.6 ± 119 BMI (kg/m2) 35.7 ± 5·9 36.0 ± 5.9 36.2 ± 5.8 Weight (kg) 100.0 ± 20·3 100.9 ±19.8 101.7 ± 19.5 Waist (cm) 107.7 ± 13·8 108.4 14.3 108.8 ± 14.1 TG (mg/dL) [128.3] [129.2] [128.3] HDL (mg/dL) [49.0] [49.0] [49.0] Metabolic 121 (40.6%) 243 (40.8%) 251 (42.4%) Syndrome† * N (%) † Metabolic syndrome present by ATP-III criteria n (%) Van Gaal et al. The Lancet 2005; 365: 1389-97. 4 RIO-Lipids: Baseline Characteristics:  RIO-Lipids: Baseline Characteristics Placebo Rimonabant (n=342) 5 mg (n=345) 20 mg (n=346) Race (white)* 329 (96.2%) 337 (97.7%) 334 (96.5%) Sex (female) 198 (57.9%) 215 (62.3%) 213 (61.6%) Age (years) 47.0 ± 10.1 48.1 ± 10.2 48.4 ± 10.0 BMI (kg/m2) 34.0 ± 3.5 34.1 ± 3.5 33.9 ± 3.3 Weight (kg) 94.9 ± 15.2 94.2 ± 14.6 93.8 ± 14.8 Waist (cm) 105.6 ± 11.5 104.8 ± 10.9 104.8 ± 11.0 TG (mg/dL) [181.4] [184.1] [187.6] HDL (mg/dL) [42.5] [42.5] [42.9] Metabolic 180 (52.9%) 191 (55.4%) 183 (53.7%) Syndrome† * N (%) † Metabolic syndrome present by ATP-III criteria n (%) Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. 5 RIO-Europe and RIO-Lipids: Weight Change at 1 Year:  RIO-Europe and RIO-Lipids: Weight Change at 1 Year Completers ITT (LOCF) Placebo Rimonabant 20 mg -10 -8 -6 -4 -2 0 0 16 32 ITT LOCF Weight change (kg) Weeks Van Gaal et al. The Lancet 2005; 365: 1389-97. Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. -1.5 -6.9 -8.6 -2.3 -3.6 -8.6 -1.8 -6.6 6 RIO-Europe : Weight Change at 1 Year:  RIO-Europe : Weight Change at 1 Year Van Gaal et al. The Lancet 2005; 365: 1389-97. 7 Weight loss ≥ 5% Weight loss ≥ 10% ITT Population Completers Placebo 5 mg 20 mg Rimonabant Rimonabant Placebo 5 mg 20 mg Rimonabant Rimonabant Proportion of Patients (%) RIO-Europe: Percent Change in HDL-C and TG Levels:  RIO-Europe: Percent Change in HDL-C and TG Levels Van Gaal, L. et al. The Lancet 2005;365:1389-97 8 RIO-Lipids: Percent Change in HDL-C and TG Levels at 1 Year:  Change in HDL-C (%) 30 25 20 15 10 5 0 0 12 24 36 52 Week P<0.001 P=0.017 11.8 15.6 22.9 RIO-Lipids: Percent Change in HDL-C and TG Levels at 1 Year Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. Rimonabant 20 mg Rimonabant 5 mg Placebo Placebo : 11. 8% R5 mg : 14.2% (ns v. placebo) R20 mg : 19.1% (p< 0.001 v. placebo) ITT, LOCF Completers Placebo : 0.0. % R5 mg : 1.2% R20 mg :-12.6% (p < 0.001 v. placebo) 10 5 0 -5 -10 -15 -20 0 12 24 36 52 Week Change in TG (%) P<0.001 +0.4 -3.6 -15.7 9 Slide10:  RIO-Lipids: Effect of Rimonabant on C-Reactive Protein and Adiponectin at 1 Year ITT-LOCF CRP levels (mg/L)*  - 0.6 mg/L P=0.007 Placebo Rimonabant 20 mg 3.6 3.2 3.7 2.7 0 1 2 3 4 5  27% * Excluding values >10 mg/L Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. C-Reactive Protein* Adiponectin D 1.6 m g/mL P=0.001 Adiponectin levels ( m g/mL) Placebo Rimonabant 20 mg 5.9 6.7 5.8 8.2 0 2 4 6 8 10 Baseline 1 Year 41% ITT-LOCF 10 Slide11:  Prevalence of the Metabolic Syndrome (ATP III Criteria) Rimonabant Placebo RIO-Lipids RIO-Europe 20 mg 5 mg Completers Only Rimonabant Baseline Completion % Change Baseline Completion % Change 38.9 25.7 33.9 42.3 27.6 34.8 44.9 15.8 64.8 Van Gaal et al. The Lancet 2005; 365: 1389-97. Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. 51.9 41.0 21.0 55.9 40.0 28.4 52.9 25.8 51.2 11 Slide12:  RIO-Europe: Overall Safety Year 1 14.5% 8.3% 9.2% Subjects discontinued due to adverse event Rimonabant Placebo 8.7% 7.5% 7.5% Subjects with any serious adverse event 87.1% 82.6% 84.3% Subjects with any adverse event 39.4% 37.3% 41.6% Overall discontinuations 20 mg n = 599 5 mg n = 603 n = 305 Rimonabant Van Gaal et al. The Lancet 2005; 365: 1389-97. 12 RIO-Europe: Discontinuation Due to Adverse Events in Year 1:  RIO-Europe: Discontinuation Due to Adverse Events in Year 1 Rimonabant 5 mg n = 603 20 mg n = 599 Psychiatric disorders Depressed mood disorders Anxiety Agitation Sleep disorders 5.2% 3.0% 0.3% 0.7% 0.0 % 3.0% 2.3% 0.0% 0.0% 0.3% 7.0% 3.7% 1.0% 0.5% 0.2% Gastrointestinal disorders Nausea Vomi ting Diarrhea 0.0% 0.0% 0.0% 0.0% 0.8% 0.2% 0.0% 0.0% 3.5% 2.3% 0.7% 0.5% Rimonabant Placebo n = 305 According to MedDRA, in at least 2 patients. One patient may report several events. Van Gaal et al. The Lancet 2005; 365: 1389-97. 13 Slide14:  RIO-Lipids: Overall Safety Year 1 15.0% 8.4% 7.0% Subjects discontinued due to adverse event Rimonabant Placebo 4.0% 5.2% 2.3% Subjects with any serious adverse event 86.7% 82.3% 81.6% Subjects with any adverse event 36.1% 37.9% 37.4% Overall discontinuations 20 mg n = 344 5 mg n = 340 n = 334 Rimonabant Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. 14 Slide15:  Despres J-P, et al. N Engl J Med. 2005;353:2121-2134. 15 Slide16:  The endocannabinoid system is a recently characterized physiologic system It modulates energy balance, feeding behavior, hepatic lipogenesis, and glucose homeostasis It is overactivated in human obesity and in animal models of genetic and diet-induced obesity Overall Summary 16 Slide17:  Endocannabinoid system stimulation centrally and peripherally favors metabolic processes, which lead to weight gain, lipogenesis, insulin resistance, dyslipidemia, and impaired glucose homeostasis CB1 blockade reverses or ameliorates these effects in non-clinical models CB1 receptor blockade with rimonabant improves multiple cardiovascular and metabolic variables in non-clinical and clinical studies: HDL-cholesterol, triglycerides, glucose, abdominal obesity, CRP, and adiponectin Effects are probably mediated by peripheral and central actions Overall Summary (Cont’d) 17

Related presentations


Other presentations created by Cubemiddle

Nuclear Energy
26. 03. 2008
0 views

Nuclear Energy

Jeopardy Template
01. 10. 2007
0 views

Jeopardy Template

Vujic IEEEMarch06
07. 10. 2007
0 views

Vujic IEEEMarch06

Fallacy
12. 09. 2007
0 views

Fallacy

how to write an introduction
06. 09. 2007
0 views

how to write an introduction

zero tolerance
06. 09. 2007
0 views

zero tolerance

Pande ICRISAT
04. 10. 2007
0 views

Pande ICRISAT

04 05 knowitall
09. 10. 2007
0 views

04 05 knowitall

intro CS p2p
27. 11. 2007
0 views

intro CS p2p

BestWorstPractices presented
04. 12. 2007
0 views

BestWorstPractices presented

Alcohol Presentacón
15. 11. 2007
0 views

Alcohol Presentacón

HIS European Exploration
15. 11. 2007
0 views

HIS European Exploration

GraphicsAtStanford mar05 san
16. 11. 2007
0 views

GraphicsAtStanford mar05 san

MCOR 384 Presentation Gallipoli
23. 11. 2007
0 views

MCOR 384 Presentation Gallipoli

Workplace Violence
14. 12. 2007
0 views

Workplace Violence

cfo presentation year end
17. 12. 2007
0 views

cfo presentation year end

Top10
25. 12. 2007
0 views

Top10

NGWA SHOW PRESENTATION
28. 12. 2007
0 views

NGWA SHOW PRESENTATION

roadmap for recovery
29. 12. 2007
0 views

roadmap for recovery

UN1001 Galvanic Corrosion
02. 01. 2008
0 views

UN1001 Galvanic Corrosion

Lec01 BASIC COUNTING
12. 09. 2007
0 views

Lec01 BASIC COUNTING

profmarins 140307
16. 11. 2007
0 views

profmarins 140307

2Monday Session3 Mulu Ketsela
29. 11. 2007
0 views

2Monday Session3 Mulu Ketsela

302 01
12. 09. 2007
0 views

302 01

SPS and SEDS Meeting 090606
06. 11. 2007
0 views

SPS and SEDS Meeting 090606

AZAASF1 POL SAFETY MAR 05
08. 11. 2007
0 views

AZAASF1 POL SAFETY MAR 05

g7x85l0kr5ko47g
07. 01. 2008
0 views

g7x85l0kr5ko47g

Sentinel1 M Davidson
07. 11. 2007
0 views

Sentinel1 M Davidson

BR ROTARY MTG 1
02. 11. 2007
0 views

BR ROTARY MTG 1

Samuels
12. 03. 2008
0 views

Samuels

schleichAPS meeting
18. 03. 2008
0 views

schleichAPS meeting

2b mobile
27. 03. 2008
0 views

2b mobile

MHSRL 20070125 backgrounder
06. 09. 2007
0 views

MHSRL 20070125 backgrounder

gnews dec
28. 11. 2007
0 views

gnews dec

2PlateTectonics
30. 03. 2008
0 views

2PlateTectonics

lecture3 351
09. 04. 2008
0 views

lecture3 351

AES Summit 4 07
10. 04. 2008
0 views

AES Summit 4 07

03forfut
17. 04. 2008
0 views

03forfut

AI 070503
22. 04. 2008
0 views

AI 070503

Pizza Fractions
12. 09. 2007
0 views

Pizza Fractions

pizza point
12. 09. 2007
0 views

pizza point

14 Howard Haimes
19. 11. 2007
0 views

14 Howard Haimes

Germany Bonn Aug 2006
02. 01. 2008
0 views

Germany Bonn Aug 2006

ENC1101 8
12. 09. 2007
0 views

ENC1101 8

Cpt4
12. 09. 2007
0 views

Cpt4

Lecture 110501
07. 11. 2007
0 views

Lecture 110501

The City of Refuge
28. 12. 2007
0 views

The City of Refuge

CS374 2004 Lecture8 Haplotypes
19. 02. 2008
0 views

CS374 2004 Lecture8 Haplotypes

mathi03
26. 02. 2008
0 views

mathi03

CN14HO
24. 02. 2008
0 views

CN14HO

PeloponnesianWar
11. 12. 2007
0 views

PeloponnesianWar

bridgedecoder
30. 12. 2007
0 views

bridgedecoder

2472CSTEforSaiminato send
10. 03. 2008
0 views

2472CSTEforSaiminato send

SL Proj1b
28. 11. 2007
0 views

SL Proj1b

P416 Lec1 S07
12. 09. 2007
0 views

P416 Lec1 S07